Megestrol for Feeding Disorders in Children
(iKanEat Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether megestrol, a medication typically used to boost appetite, can help children who rely on feeding tubes transition to eating by mouth. Participants will receive either megestrol or a placebo (a dummy treatment with no active ingredients) as part of a behavioral feeding program over 24 weeks. The goal is to determine if megestrol can ease the transition away from tube feeding. Children aged 9 months to 9 years who receive most of their nutrition through a feeding tube and have feeding problems may be suitable for this trial. As a Phase 4 trial, this research examines how an already FDA-approved and effective treatment can benefit more patients, contributing to understanding its broader impact.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but children receiving oral or inhaled steroids cannot participate.
What is the safety track record for megestrol acetate and the iKanEat Behavioral Intervention?
Research has shown that megestrol is usually well-tolerated by patients. In previous studies, participants experienced only mild side effects, which are generally not serious. These may include slight changes in skin color, diarrhea, or dizziness. Serious side effects are rare. The FDA has approved megestrol for treating weight loss in certain conditions, indicating a known safety record.
Megestrol is a type of steroid and carries some risks, especially for those with kidney issues. It is mostly safe when used properly, but like any medication, monitoring for side effects and consulting a doctor if they occur is important.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about Megestrol Acetate for feeding disorders in children because it offers a unique approach compared to standard nutritional and behavioral therapies. Unlike traditional methods, which often rely on intensive feeding interventions and support, Megestrol acts as an appetite stimulant, potentially making the weaning process from tube feeding to oral feeding smoother and more effective. Its glucocorticoid effect, although not fully understood, is believed to be key in promoting appetite and weight gain, providing a promising option for improving nutritional intake in young children.
What evidence suggests that this trial's treatments could be effective for feeding disorders in children?
Research has shown that megestrol acetate, one of the treatments in this trial, can help children gain weight. One study found that children with serious health issues who took megestrol gained more weight than those who took a placebo, a pill with no active medicine. In this trial, some participants will receive megestrol to help increase appetite and assist in transitioning from tube feeding to eating normally. Past studies have proven this treatment safe and effective for similar cases. Although the exact mechanism is unknown, it is believed to increase appetite by acting like a steroid.678910
Are You a Good Fit for This Trial?
The iKanEat trial is for children aged 9 months to 9 years with chronic oral food refusal who rely on tube feeding for over 80% of their daily calories. They must have the necessary oral and behavioral skills for eating, as assessed by a multidisciplinary team, and be medically stable to transition from tube to oral feeding.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either megestrol or placebo as part of a 24-week behavioral feeding protocol to transition from tube to oral feedings.
Megestrol Tapering
Megestrol is dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of child quality of life and parent stress.
What Are the Treatments Tested in This Trial?
Interventions
- iKanEat Behavioral Intervention
- Megestrol Acetate
Trial Overview
This study tests if megestrol combined with a behavioral feeding protocol helps kids switch from tube to mouth feeding. It's randomized: half get megestrol, half get placebo; neither doctors nor participants know who gets which. The treatment lasts for 24 weeks across multiple centers.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Megestrol is a steroid and progestational drug FDA approved for treating anorexia or weight loss in patients with acquired immunodeficiency syndrome. Its use in the current protocol is "off label" to stimulate appetite in tube-fed infants and toddlers who are weaning from tube feedings and learning to eat. The precise mechanism of action that leads to increased appetite and weight gain is unknown, but is probably related to megestrol's glucocorticoid effect. The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable.
Subjects randomized to the placebo protocol will receive a placebo syrup identical in taste and smell to megestrol at the same intervals as those in the megestrol group but the syrup will contain no active ingredients.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Kansas Medical Center
Lead Sponsor
Citations
iKanEat: protocol for a randomized controlled trial of megestrol ...
Hypothesis 1. Children randomized to the megestrol group will be more successful in making the transition to oral feeding (defined as obtaining at least 90% of ...
A randomized, double-blind, placebo-controlled clinical ...
Conclusion: In children with high-risk malignancies, MA resulted in significant increases in mean percent weight change compared to placebo.
Evaluation and Management of Pediatric Feeding Disorder
Pharmacological treatment with appetite stimulants (e.g., cyproheptadine and megestrol acetate) is commonly used to improve appetite and weight ...
A randomized, double‐blind, placebo‐controlled clinical ...
Primary outcome was the difference between groups in mean percent weight change from beginning to end of the study period. Secondary outcomes ...
5.
publications.aap.org
publications.aap.org/pediatrics/article/99/3/354/67342/Megestrol-Acetate-Treatment-of-Growth-Failure-inMegestrol Acetate Treatment of Growth Failure in Children ...
In two published case series, enteral tube feeding significantly increased weight and weight:height z-scores without affecting height.
MEGACE® ES (megestrol acetate) oral suspension
Megestrol acetate is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired ...
Megestrol (oral route) - Side effects & dosage
This medicine may cause adrenal gland problems. Check with your doctor right away if you have darkening of the skin, diarrhea, dizziness, ...
Megace® ES (megestrol acetate, USP) Oral Suspension
The pharmacokinetics of megestrol acetate has not been studied in specific population, for example, pediatric, renal impairment, and hepatic impairment.
Megestrol - StatPearls - NCBI Bookshelf - NIH
Generally, toxicity to megestrol is very mild, rated on a scale of Grade 0 or 1. No serious adverse drug reactions have resulted from megestrol ...
Megestrol acetate: Uses, Interactions, Mechanism of Action
Megestrol acetate is a progestin that is administered orally to treat anorexia and cachexia or serious unexplained weight loss and is also used as an ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.